Leerink

Shares of bluebird bio Inc (NASDAQ: BLUE) are up 360 percent over the last two years, but Leerink said the stock’s losing steam. The Rating Leerink analyst Michael Schmidt downgraded Bluebird from Outperform to Market Perform and increased the price target from $162 to $194. The Thesis...

Here we have it: the largest deal of 2017. CVS Health Corp (NYSE: CVS) confirmed Monday its agreement to acquire Aetna Inc (NYSE: AET) as a standalone business unit for about $207 per share. The parties intend to close the deal in the second half of 2018 to yield $750 million in near-term synergies...

The performance of the tardive dyskinesia drug Ingrezza had sell-side analysts gushing over Neurocrine Biosciences, Inc. (NASDAQ: NBIX)'s third-quarter results. Given the buoyancy surrounding Ingrezza, analysts scrambled to designate Neurocrine as their top mid-cap pick. Ingrezza...

Shares of Thermo Fisher Scientific Inc. (NYSE: TMO) came under heavy selling pressure last Friday, which continued into Monday's trading session amid ongoing concerns that Amazon.com, Inc. (NASDAQ: AMZN) is looking to enter lab supplies and other health care related businesses. But Thermo Fisher's...

Rumors that Amazon.com, Inc. (NASDAQ: AMZN) may soon be jumping into the pharmacy business have weighed on drug retailers Walgreens Boots Alliance Inc (NASDAQ: WBA) and CVS Health Corp (NYSE: CVS). However, pharmacy benefit managers, which serve as middlemen between insurers and pharmaceutical...

Last week, Leerink analyst David Larsen said that it’s only a matter of time before Amazon.com, Inc. (NASDAQ: AMZN) takes the plunge into the pharmacy business and that Amazon could be selling prescription drugs within two years’ time. On Monday, Bernstein analyst Lance Wilkes said...

Pharmacy and health care investors should brace themselves — Amazon.com, Inc (NASDAQ: AMZN) is coming. In a pair of new research notes out this week, analysts at Leerink said it’s not a matter of if Amazon will make a move into the prescription drug business, it’s a matter of...

Buy the rumor, sell the news is an adage many traders vouch by. With the market operating on a forward-looking basis, any imminent event or rumor could send traders piling into the stock only to liquidate when the news is released or the rumor is confirmed. By doing so, they make a neat profit....

With a balanced take on many newsworthy items regarding ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) released Wednesday, Leerink reiterated its Market Perform rating on the shares of the company. At time of publication, shares of Acadia Pharma were up 1.12 percent at $38.73 in Friday's pre-...

Shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) were trading higher by more than 12 percent Wednesday after the company released encouraging clinical trial data. The company's therapy showed a greater improvement in muscle and lung function for people suffering from Pompe, a rare disease...

ProQR Therapeutics NV (NASDAQ: PRQR), a nano-cap pre-clinical stage bio pharmaceutical company engaged in the discovery and development of ribonucleic acid-based therapeutics for the treatment of severe genetic disorders, announced the completion of a phase 1b study Monday, which helped boost...

Analysts at Leerink turned bullish on Dova Pharmaceuticals Inc (NASDAQ: DOVA) after a competitor to the clinical-stage pharmaceutical company reported disappointing results from a phase 3 trial. Japan-based Shionogi announced Monday that a phase 3 trial investigating thrombopoietin receptor agonist...

Leerink downgraded shares of Exelixis, Inc. (NASDAQ: EXEL) and lowered its price target, citing an $8.6 billion diluted market cap. The firm thinks the consensus estimates now adequately reflect the commercial potential for Cabometyx in renal cell carcinoma, and the valuation implied additional...

Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares are skyrocketing Friday in reaction to its announcement of positive preliminary data from two ongoing clinical trials of its non-small cell lung cancer, or NSCLC, candidate sitravatinib. The company said the data will be presented at the IASLC 2017...

Align Technology, Inc. (NASDAQ: ALGN) shares soared after reporting record second-quarter results that saw a solid earnings and sales beat. Align, which is the manufacturer of Invisalign, could see an inflection point in its teen segment, according to a note from Leerink analyst Richard Newitter....